



**HAL**  
open science

## **Impacto del tipo de mascarilla en la eficacia de la ventilación no invasiva en pacientes con enfermedad neuromuscular: un ensayo clínico aleatorizado cruzado**

Antoine Léotard, Marius Lebret, Najeh Daabek, Hélène Prigent, Marie Destors, Christelle Saint-Raymond, Amélie Sagniez, Karl Leroux, Renaud Tamisier, Frédéric Lofaso, et al.

### ► To cite this version:

Antoine Léotard, Marius Lebret, Najeh Daabek, Hélène Prigent, Marie Destors, et al.. Impacto del tipo de mascarilla en la eficacia de la ventilación no invasiva en pacientes con enfermedad neuromuscular: un ensayo clínico aleatorizado cruzado. Archivos de Bronconeumología, 2021, 57 (4), pp.273-280. 10.1016/j.arbres.2020.05.024 . hal-03218459

**HAL Id: hal-03218459**

**<https://hal.science/hal-03218459>**

Submitted on 24 Apr 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

## ORIGINAL

# Impact of interface type on noninvasive ventilation efficacy in patients with neuromuscular disease: a randomized cross-over trial

**Authors :** Antoine Léotard <sup>1,3\*</sup>, Marius Le Bret <sup>4,5\*</sup>, Najeh Daabek <sup>5</sup>, Hélène Prigent <sup>2,3</sup>, Marie Destors <sup>4,6</sup>, Christel Saint-Raymond <sup>7</sup>, Amélie Sagniez <sup>8</sup>, Karl Leroux <sup>9</sup>, Renaud Tamisier <sup>4,6</sup>, Frédéric Lofaso <sup>2,3</sup>, Jean Louis Pépin <sup>4,6\*\*</sup>, Jean Christian Borel <sup>4,5\*\*</sup>.

<sup>1</sup> Département de physiologie, explorations fonctionnelles, unité des pathologies du sommeil, AP-HP, Hôpital Raymond Poincaré, 104, boulevard Raymond-Poincaré, 92380 Garches, France

<sup>2</sup> Département de physiologie, explorations fonctionnelles, unité de physiologie respiratoire, AP-HP, Hôpital Raymond Poincaré, 104, boulevard Raymond-Poincaré, 92380 Garches, France

<sup>3</sup> Université Versailles–Saint-Quentin-en-Yvelines, « End:icap » U1179 Inserm, UFR Des sciences de la sante–Simone-Veil, Versailles, France

<sup>4</sup> Univ. Grenoble Alpes, Inserm, CHU Grenoble Alpes, HP2, 38000 Grenoble, France

<sup>5</sup> AGIR à dom. Association, Meylan, F-38240 France

<sup>6</sup> Laboratoire Sommeil et exercice, pole thorax-vaisseaux, CHU Grenoble Alpes

<sup>7</sup> Unité de pneumologie, CHU Grenoble Alpes

<sup>8</sup> Adep Assistance, Le Narval A1 - 29 rue des Hautes Pâtures 92000 Nanterre

<sup>9</sup> ASV Santé, 125, Avenue Louis Roche, 92230 GENNEVILLIERS

\* Co first author \*\* Co senior author

### Corresponding author:

**Dr Antoine Léotard**

Adress : 104 Boulevard Raymond Poincaré,

Post code : 92380

City : Garches

Country : France

E-mail : antoine.leotard@aphp.fr

Phone : +33(0)1.47.10.79.40

**Main text Word count:** 2489

*Registration number:* NCT03458507

*Data sharing statement:*

Individual participant data that underlie the results reported in this article after deidentification (including data dictionaries) will be shared beginning 3 months and ending 5 years following article publication with researchers who provide a methodologically sound proposal. Data will be shared for analyses to achieve aims in the approved proposal. Proposals should be directed to antoine.leotard@aphp.fr. To gain access, data requestors will need to sign a data access agreement.

*Author contributions:*

Substantial contributions to study conception and design, acquisition of data, or analysis and interpretation of data: A.L., J.C.B., J.L.P., F.L., H.P., M.L., R.T., M.D., C.SR,A.S., K.L.. Statistical analyses: N.D. Drafting the article or revising the article critically for important intellectual content: A.L., J.C.B., F.L., J.L.P., M.L.. Final approval of the version to be published: all co-authors. Guarantor of the paper, taking responsibility for the integrity of the work as a whole: A.L.

*Grant:*

This study received a grant from “Association Française contre les Myopathies – AFM”.

*Acknowledgments:*

We would like to thank Richard Yvinec, Vincent Delord, Mickael Berlusconi, Steffy Masucco, Galina Penkov, Sebastien Bailly, Marie Peeters, Mélanie Lopez, Pierre Ansay to have contribute to this work with human or technical assistance.

## ABSTRACT

**Background and objective:** Around 25% of patients with neuro-muscular diseases (NMD) are treated by home noninvasive ventilation (NIV) through an oronasal mask. However, there is growing evidence that nasal masks require lower NIV pressures and result in fewer residual obstructive events. We hypothesized that nasal masks would improve efficacy and reduce side effects compared to oronasal masks in this population.

**Methods:** open label, cross-over, randomized, study in 2 tertiary care hospitals. Patients with NMD treated by home NIV were randomized for one-week periods to nasal and oronasal interfaces respectively (cross-over). At the end of each period, nocturnal polygraphy (monitoring mouth opening) under NIV, synchronized with transcutaneous partial pressure in CO<sub>2</sub> (tcCO<sub>2</sub>) was performed. Data were collected from the NIV built-in software and NIV side-effects were collected. Intention-to-treat and per protocol analyses were performed. The primary outcome was mean nocturnal SpO<sub>2</sub>. The secondary outcomes were: percentage of sleep with SpO<sub>2</sub><90%, oxygen desaturation index (ODI), mean tcCO<sub>2</sub>, mean duration of mouth opening during sleep, level of non-intentional leaks and side-effects.

**Results:** Thirty patients with NMD were included. There were no between-group differences for either the primary or secondary outcomes. Post-hoc comparisons showed that changing between interfaces reduced NIV efficacy: mean nocturnal SpO<sub>2</sub> (p=0.04), ODI (p=0.01), mean tcCO<sub>2</sub> (p=0.048), side-effects (p=0.008).

**Conclusion:** Nasal masks did not improve NIV efficacy or reduce side effects compared to oronasal masks in patients with NMD treated by home NIV. The efficacy of NIV is reduced during the transition to another interface, requiring close monitoring.

## Keywords

**Neuromuscular diseases, non-invasive ventilation, nasal mask, oronasal mask**

## Impacto del tipo de mascarilla en la eficacia de la ventilación no invasiva en pacientes con enfermedad neuromuscular: un ensayo clínico aleatorizado cruzado

### RESUMEN

**Antecedentes y objetivo:** Alrededor del 25% de los pacientes con enfermedades neuromusculares (ENM) son tratados mediante ventilación no invasiva (VNI) a través de una máscara oronasal. Sin embargo, existen crecientes indicios de que las máscaras nasales requieren presiones de VNI más bajas y resultan en menos eventos obstructivos residuales. Nuestra hipótesis fue que las máscaras nasales mejorarían la eficacia y reducirían los efectos secundarios en comparación con las máscaras oronasales en esta población.

**Métodos:** Estudio abierto, cruzado, aleatorizado, en dos hospitales de atención terciaria. Los pacientes con ENM tratados mediante VNI domiciliaria fueron aleatorizados durante períodos de una semana de duración a las mascarillas nasales y oronasales, alternativamente (cruzado). Al final de cada período, se realizó una polisomnografía nocturna (con monitorización de la apertura bucal) con VNI, sincronizada con la medición transcutánea de la presión parcial de CO<sub>2</sub> (tcCO<sub>2</sub>). Los datos se recopilaron utilizando el software integrado en la VNI y se recogieron los efectos secundarios de la VNI. Se realizaron análisis por intención de tratar y por protocolo. El criterio de valoración principal fue la SpO<sub>2</sub> nocturna media. Los criterios secundarios fueron: porcentaje de sueño con SpO<sub>2</sub> <90%, índice de desaturación de oxígeno (IDO), tcCO<sub>2</sub> media, duración media de la apertura bucal durante el sueño, nivel de fugas no intencionales y efectos secundarios.

**Resultados:** Se incluyeron treinta pacientes con ENM. No hubo diferencias entre los grupos para los resultados primarios o secundarios. Las comparaciones *a posteriori* mostraron que cambiar mascarillas reducía la eficacia de la VNI: SpO<sub>2</sub> nocturna media ( $p = 0,04$ ), IDO ( $p = 0,01$ ), tcCO<sub>2</sub> media ( $p = 0,048$ ), efectos secundarios ( $p = 0,008$ ).

**Conclusión:** Las máscaras nasales no mejoraron la eficacia de la VNI ni redujeron los efectos secundarios en comparación con las máscaras oronasales en pacientes con ENM tratados con VNI domiciliaria. La eficacia de VNI se reduce durante la transición a otra máscara, lo que requiere una estrecha vigilancia.

**Palabras clave:**

**Enfermedades neuromusculares, ventilación no invasiva, mascarilla nasal, mascarilla oronasal**

## INTRODUCTION

Home Noninvasive Ventilation (NIV) is the reference treatment for chronic alveolar hypoventilation in patients with neuro-muscular diseases (NMD)(1,2). NIV can be provided through different types of interfaces, the most common of which are nasal masks and oronasal masks. The choice of interface is very important as it affects both the efficiency of the NIV and patient adherence, which is essential for effective treatment. Prior to initiation of NIV, clinicians must therefore determine which interface will provide the most efficient treatment but will also be comfortable for the patient so that they do not abandon the treatment.

Nasal masks are the most commonly used interface for home NIV in patients with NMD(3). However, persistent unintentional leaks, especially through the mouth trigger nasal congestion and/or nasopharyngeal and mouth dryness. Mouth leaks can also reduce NIV efficacy and impair sleep quality(4). Oronasal masks covering the nose and mouth are thus commonly proposed to patients in these situations(5).

The decision to choose an oronasal mask is most often based on self-reported symptoms (especially leaks and side effects). Data collected from the NIV built-in software may also lead clinicians and home care providers to suspect leakage due to mouth opening. However, the proportion of real sleep time spent with an open mouth is usually not objectively documented(6) and once an oronasal mask has been prescribed, a shift back to a nasal mask is almost never considered during follow-up as mouth leaks are considered to be a permanent problem.

About 25% of patients with NMD who are treated with nocturnal NIV at home use an oronasal mask (3,7,8) but clinical reality shows that there is great heterogeneity of use between different countries, regions or units. A recent analysis showed that NMD patients who used oronasal interfaces were older and had higher BMI than patients who used nasal mask; two factors which are linked to obstructive apneas. Accordingly, positive expiratory pressures (PEP) set on the NIV were also higher with oro-nasal masks(9). This type of interface have been reported to increase upper-



airway (UA) resistance by pushing the mandible backward, which in turn facilitates occurrence of upper airway obstruction(10,11).

Very few studies have compared, using appropriate methodology, the efficacy of nasal mask versus oronasal mask in patients treated by long term nocturnal NIV(12,13). The aim of this study was to compare the efficacy and rate of side effects between nasal and oronasal masks in patients with NMD. We hypothesized that the application of an oronasal mask might compromise nocturnal mechanical ventilation and gas exchange by favoring pharyngeal closure or increased resistance in patients already prone to upper airway obstruction due to their underlying disease or to their maxillofacial profile. Thus, the use of a nasal mask (that does not reduce upper airway stability) would provide more effective NIV with fewer side effects compared to an oronasal mask.

## METHODS

*(see details in online supplement)*

### ***Trial design***

We performed an open label, cross-over, randomized, study in 2 tertiary care hospitals in France. Both hospitals had substantial experience in the management of NMD and treatment with NIV. The study was approved by our ethics committee (CPP Nord-ouest II) following French legislation, and written informed consent was obtained from all patients. The trial was registered in ClinicalTrials.Gov (number NCT03458507).

### ***Participants***

Patients with NMD treated with home NIV who were followed by the participating centers were screened for eligibility between May 2018 and May 2019. The inclusion criteria were: adults (>18 years old) treated with nocturnal non-invasive ventilation <15 hours/day (to exclude patient with severe respiratory insufficiency in which transition period should have been at risk) and diagnosed with a NMD (Becker muscular dystrophy, facio-scapulo-humeral dystrophy, limb-girdle dystrophy, myotonic dystrophy, Duchenne muscular dystrophy). Exclusion criteria were: occurrence of an acute cardiorespiratory or ear-nose-throat event during the month prior to inclusion, rapidly progressive NMD (such as ALS), severe nasal obstruction and maxillofacial deformities or previous upper airway surgery preventing the usage of one type of mask (nasal or oronasal).

### ***Interventions***

*Inclusion visit.* Patients tested the interface they did not usually use (i.e. nasal mask for those treated with oronasal masks or oronasal mask for those treated with nasal masks) during a one-hour diurnal NIV session. The most appropriate alternative mask (in terms of brand and size) was chosen for each patient in order to minimize leakage and maximize comfort.

*Follow up.* At the end of the inclusion visit, patients were randomized to start either with their usual or alternative interface. During the week with the alternative interface, patients were asked to use this new interface with the aim to sleep overnight with it. During the week with the usual interface, patients were asked to pursue their treatment as usual. The number and nature of interface-related problems reported by patients and/or the need for a home care provider visit were collected during both weeks.

At the end of each week, an unattended type III nocturnal polygraphy under NIV was performed at home using a Somnolter® (Nomics, Liege, Belgium) device synchronized with transcutaneous partial pressure in CO<sub>2</sub> (PtcCO<sub>2</sub>) monitoring by SenTec V-Sign™ System. This polygraph also records mandibular mouth opening.

Assessment of NIV side-effects was performed with the Modified SECI questionnaire(14) (for each commonly reported side effect, the patient is asked to rate the frequency, magnitude and perceived impact on adherence on a five-point Likert-type scale).

### ***Outcomes***

Patients were evaluated on two occasions, at the end of each week with either the usual or the alternative interface (cross-over). The primary objective was to compare mean nocturnal oxygen saturation between oronasal masks and nasal masks (Mean nocturnal SpO<sub>2</sub>, measured by polygraphy, Somnolter®). We also assessed the following exploratory secondary outcomes: percentage of sleep with SpO<sub>2</sub><90% (polygraphy, Somnolter®); oxygen desaturation index (polygraphy, Somnolter®); mean nocturnal transcutaneous partial pressure in CO<sub>2</sub> (PtcCO<sub>2</sub>, SenTec V-Sign™); mean mouth opening during sleep (polygraphy, Somnolter®); level of non-intentional leaks (percentage of recording time spend with leaks assessed by SomnoHolter®); the side-effects for each type of mask (Modified SECI).

### ***Randomization***

Participants were randomized (computer-generated random numbers list) to either begin the trial with their usual interface (for one week) or the alternative interface (for one week) in order to allow a balance between the numbers of patients who would begin with their usual interface versus with an alternative interface, the randomization was stratified for the type of interface usually used by the patient.

### ***Sample size***

Very few studies have compared nasal and oronasal masks for noninvasive ventilation in chronic respiratory failure(10,12,13). Therefore, in this pilot study, the sample size estimation was based on our inclusion capability and was based on the following: 1) at least 100 eligible patients were followed in the two participating centers, 2) 25% to 30% of patients with NMD use oronasal masks and we wanted to recruit equal numbers of patients who usually used oronasal masks and nasal masks and 3) we estimated that about 50% of eligible patients would accept to participate. Therefore, we planned to 30 patients (15 with nasal mask and 15 patients with oronasal mask). This sample size was sufficiently powered to detect a mean difference of mean nocturnal Spo<sub>2</sub> of  $2 \pm 2\%$  (considered as clinically significant) between oronasal versus nasal mask (alpha=0.05, power=80%).

### ***Statistical analysis***

A treatment effect test, a period effect test, and a test for the interaction between treatment and period were used to assess respective effect of treatment (nasal versus oronasal), treatment sequence, and the first-order carryover risk.

Paired student t-tests were conducted to assess differences between the two interfaces for normally distributed outcomes. Wilcoxon signed-rank tests for paired values were used to compare non-normally distributed outcomes. Significance was set at  $p < 0.05$ . Missing data were not imputed.

All randomized patients were analyzed in intention to treat (ITT): if a patient did not tolerate the alternative interface, polygraphy was performed with their usual interface and data collected during

this evaluation was used in the analysis. A per-protocol (PP) was secondarily performed using data from patients who completed both polygraphies with the appropriate masks without any protocol deviation. Finally, a post-hoc comparison using the same statistical models was performed to compare the usual and alternative interfaces to assess the impact of mask change among those patients.

## RESULTS

### ***Recruitment***

The study flow is depicted in figure 1, 30 patients with NMD were included. Among them, 13 used an oronasal mask at home. During the week with the alternative interface, 5 patients had major intolerances (2 with the nasal mask and 3 with the oro-nasal) despite home care provider interventions and thus resumed the use of their usual interface (Figure 1).

Table 1 presents the anthropometric characteristics of patients and ventilator settings. Patients were middle aged and equally distributed in terms of sex. Myotonic dystrophy was the most represented neuromuscular disorder (36.7%). Pressure support mode was used by 86.7% of patients with no differences in IPAP and EPAP settings between those who usually used nasal and those who used oronasal masks. There was no difference in mean NIV adherence, residual AHI or tidal volume estimated by NIV built-in software between patients who used nasal and those who used oronasal interfaces.

### ***Primary outcome***

There were no significant differences in mean nocturnal SpO<sub>2</sub> between the interfaces (ITT,  $p=0.73$ ; PP,  $p=0.59$ ) (Figure 2).

### ***Secondary outcomes***

There were no differences in secondary outcomes between the interfaces (Figure 2): percentage of sleep recording spent with SpO<sub>2</sub><90% (ITT,  $p=0.33$ ; PP,  $p=0.57$ ); oxygen desaturation index (ITT,  $p=0.74$ ; PP,  $p=0.59$ ); mean nocturnal transcutaneous partial pressure in CO<sub>2</sub> (ITT,  $p=0.13$ ; PP,  $p=0.11$ ); mean mouth opening during sleep (ITT,  $p=0.1931$ ; PP,  $p=0.054$ ); level of non-intentional leaks (ITT,  $p=0.58$ ; PP,  $p=0.80$ ) or side-effects according to each type of mask (ITT,  $p=0.46$ ; PP,  $p=0.98$ ). Additionally, no differences were found between masks in terms of mean NIV adherence, residual AHI, nadir SpO<sub>2</sub>, time spent with leaks or time spent with tcCO<sub>2</sub> > 55mmHg.

There were no differences in the ratio of patients who reported interface problems or the number of home care provider interventions between interfaces (Table 2).

#### **Post hoc analysis of interface transitions (Figure 3)**

Post-hoc comparisons showed that changing from one interface to another reduced NIV efficacy: oxygen desaturation index (ITT,  $p=0.01$ ; PP,  $p=0.01$ ); mean nocturnal transcutaneous partial pressure in CO<sub>2</sub> (ITT,  $p=0.048$ ; PP,  $p=0.09$ ); side-effects (ITT,  $p=0.008$ ; PP,  $p=0.02$ ).

During the week with the alternative interface, mask problems ratio and home care provider intervention numbers were higher ( $p < 0.01$ ) and mean adherence was lower ( $p=0.02$ ) (Table 2). Accordingly, patients perceived an impact on adherence during the week with the alternative interface (Table 3).

Complaints reported by participants about the alternative interface were predominantly mask intolerance, leaks, mouth dryness and cutaneous lesions. Problems relating to the underlying condition and impaired autonomy were reported especially with the use of an oronasal interface (impaired communication leading to the incapacity to call for help if needed, compromised vocal command device use, compromised hydration autonomy at night, etc. )

## DISCUSSION

This original randomized cross-over study found no differences between nasal and oronasal masks in terms of nocturnal NIV efficacy and NIV tolerance. However, during the transition between the interfaces mean nocturnal SpO<sub>2</sub> and adherence decreased and oxygen desaturation, mean nocturnal tcCO<sub>2</sub> and side effects increased.

In a previous RCT that included a heterogeneous group of patients with chronic respiratory failure, Willson *et al.* reported poorer quality of sleep, impaired tolerance (less comfort, more perceived leaks) with the use of oronasal masks compared to nasal masks(13). However, similarly to the present study, they also found no differences in terms of nocturnal gas exchange or sleep disordered breathing between the two interfaces. In Willson *et al.*'s study, all subjects were treated with nocturnal NIV at home via a nasal mask(13). Therefore, the reduced tolerance reported with oronasal mask may simply reflect difficulty switching from the usual interface to another. This hypothesis is supported by the results of the post-hoc analyses in the present study.

We hypothesised that the oronasal mask might increase upper airway obstruction and jeopardize NIV efficacy. This was based on a recent case report in a patient with ALS (without bulbar involvement) that showed that use of an oronasal mask with NIV caused persistent obstructive respiratory events, with oxygen desaturations, sleep fragmentation and persistent sleep hypercapnia(10). In the field of obstructive sleep apnea, the impact of the mask type has been more extensively assessed in patients treated with continuous positive airway pressure (CPAP). Similar reports of persistent obstructive respiratory events with the use of oronasal masks have been published(15–17). Although, the exact mechanisms have not been completely elucidated, two main hypotheses have been put forward: i) mechanical constraint of the chin induced by the oronasal mask and traction of straps may push the mandible posteriorly during sleep(18); ii) air pressure blowing into the mouth and oral breathing may push the tongue backward and reduce pharyngeal patency(15,19,20). The results of the present study did not suggest that oronasal masks increased



upper airway obstruction, despite the fact that this is a common occurrence in patients with neuromuscular diseases. Although mask-related upper airway obstruction has been shown to be highly prevalent in patients with neuromuscular disorders, it may be more prevalent in patients with ALS not included in the present study(11). Indeed, the level of EPAP was relatively low both in patients with nasal and oronasal mask suggesting that the patients included may be unlikely to have severe upper airway collapsibility. Finally, our specialized nurses are strongly aware of this issue and thus teach patients and primary caregivers to avoid any over tightening of mask straps during the positioning.

The patients included in this study, were all treated with home nocturnal NIV and the median adherence was greater than 7 hours/night. The post hoc analysis showed that during the transition to a new interface, NIV efficacy was reduced and side effects increased. This information is important for clinicians since in practice, interfaces are often changed by home care providers or on the patient's own initiative with no systematic medical supervision. In the present study, despite close follow up during the week of change (and in-hospital initial mask choice and adjustment), mean nocturnal SpO<sub>2</sub> decreased and mean tcCO<sub>2</sub> increased as did the oxygen desaturation index and the number of side effects occurs. To our knowledge, no study has previously addressed the acute consequences and risks related to mask change in patients with neuromuscular diseases with nocturnal NIV. Our results suggest that information regarding changing masks should be provided during patient and caregiver education to ensure that appropriate medical supervision is sought, should they decide to change interface.

### ***Limitations***

Although our study was powered to detect a mean difference of mean nocturnal Spo<sub>2</sub> of  $2 \pm 2\%$  between oronasal and nasal masks, it is possible that the study was under powered due to the fact 5 patients did not tolerate the alternative interface.

The patients were not naive to NIV and the heterogeneity of the underlying diseases and level of autonomy could also have impacted the results. Yet, this recruitment reflects daily practice in tertiary care hospitals who deals with respiratory care in NMD which remain rare diseases (therefore it would have not been possible to complete this study in a reasonable time-frame with naive patients).

In our study, oronasal mask patients appeared to not have significant enough issues with upper airway resistance. We should have focused on more carefully selected patients with high upper airway resistance, residual events or low efficacy of oronasal NIV and assess the benefits to switch interface in those patients.

Finally, the period of adaptation to the alternative interface might have been too short.

Because of the high specificity of the sample included, the results of this study should not be extrapolated to other populations such as people with obesity hypoventilation syndrome and chronic obstructive pulmonary disease.

## **CONCLUSION**

This study found no difference between oronasal and nasal masks in patients with neuromuscular diseases under long term nocturnal NIV in terms of treatment tolerance and efficacy. The results showed that treatment efficacy may be reduced during transition between interfaces, thus changes in masks should be carried out under close medical supervision.

## REFERENCES

1. Annane D, Orlikowski D, Chevret S. Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders. *Cochrane Database Syst Rev* 2014;CD001941.
2. Leger P, Bedicam JM, Cornette A, Reybet-Degat O, Langevin B, Polu JM, et al. Nasal intermittent positive pressure ventilation. Long-term follow-up in patients with severe chronic respiratory insufficiency. *Chest* 1994;105:100-5.
3. Lofaso F, Prigent H, Tiffreau V, Menoury N, Toussaint M, Monnier AF, et al. Long-term mechanical ventilation equipment for neuromuscular patients: meeting the expectations of patients and prescribers. *Respir Care* 2014;59:97-106.
4. Teschler H, Stampa J, Ragette R, Konietzko N, Berthon-Jones M. Effect of mouth leak on effectiveness of nasal bilevel ventilatory assistance and sleep architecture. *Eur Respir J* 1999;14:1251-7.
5. McKim DA, Road J, Avendano M, Abdool S, Cote F, Duguid N, et al. Home mechanical ventilation: a Canadian Thoracic Society clinical practice guideline. *Can Respir J* 2011;18:197-215.
6. Lebreton M, Arnol N, Contal O, Martinot JB, Tamisier R, Pepin J-L, et al. Nasal obstruction and male gender contribute to the persistence of mouth opening during sleep in CPAP-treated obstructive sleep apnoea. *Respirol Carlton Vic* 2015;20:1123-30.
7. Rabec C, Georges M, Kabeya NK, Baudouin N, Massin F, Reybet-Degat O, et al. Evaluating noninvasive ventilation using a monitoring system coupled to a ventilator: a bench-to-bedside study. *Eur Respir J* 2009;34:902-13.
8. Pasquina P, Adler D, Farr P, Bourqui P, Bridevaux PO, Janssens J-P. What does built-in software of home ventilators tell us? An observational study of 150 patients on home ventilation. *Respir Int Rev Thorac Dis* 2012;83:293-9.
9. Leotard A, Lebreton M, Prigent H, Arnol N, Pépin J-L, Hartley S, et al. [Factors associated with the type of mask used during nocturnal NIV in patients with neuromuscular disorders]. *Rev Mal Respir* 2020.
10. Vrijsen B, Buyse B, Belge C, Testelmans D. Upper airway obstruction during noninvasive ventilation induced by the use of an oronasal mask. *J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med* 2014;10:1033-5.
11. Schellhas V, Glatz C, Beecken I, Okegwo A, Heidbreder A, Young P, et al. Upper airway obstruction induced by non-invasive ventilation using an oronasal interface. *Sleep Breath Schlaf Atm* 2018;22:781-8.
12. Fernandez R, Cabrera C, Rubinos G, Pando A, Galindo R, Rodríguez F, et al. Nasal versus oronasal mask in home mechanical ventilation: the preference

- of patients as a strategy for choosing the interface. *Respir Care* 2012;57:1413-7.
13. Willson GN, Piper AJ, Norman M, Chaseling WG, Milross MA, Collins ER, et al. Nasal versus full face mask for noninvasive ventilation in chronic respiratory failure. *Eur Respir J* 2004;23:605-9.
  14. Broström A, Arestedt KF, Nilsen P, Strömberg A, Ulander M, Svanborg E. The side-effects to CPAP treatment inventory: the development and initial validation of a new tool for the measurement of side-effects to CPAP treatment. *J Sleep Res* 2010;19:603-11.
  15. Fleck RJ, Mahmoud M, McConnell K, Shott SR, Gutmark E, Amin RS. An adverse effect of positive airway pressure on the upper airway documented with magnetic resonance imaging. *JAMA Otolaryngol-- Head Neck Surg* 2013;139:636-8.
  16. Nascimento JA, de Santana Carvalho T, Moriya HT, Fernandes PHS, de Andrade RGS, Genta PR, et al. Body Position May Influence Oronasal CPAP Effectiveness to Treat OSA. *J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med* 2016;12:447-8.
  17. Schorr F, Genta PR, Gregório MG, Danzi-Soares NJ, Lorenzi-Filho G. Continuous positive airway pressure delivered by oronasal mask may not be effective for obstructive sleep apnoea. *Eur Respir J* 2012;40:503-5.
  18. Borel J-C, Gakwaya S, Masse J-F, Melo-Silva CA, Sériès F. Impact of CPAP interface and mandibular advancement device on upper airway mechanical properties assessed with phrenic nerve stimulation in sleep apnea patients. *Respir Physiol Neurobiol* 2012;183:170-6.
  19. Madeiro F, Andrade RGS, Piccin VS, Pinheiro G do L, Moriya HT, Genta PR, et al. Transmission of Oral Pressure Compromises Oronasal CPAP Efficacy in the Treatment of OSA. *Chest* 2019;156:1187-94.
  20. Andrade RGS, Viana FM, Nascimento JA, Drager LF, Moffa A, Brunoni AR, et al. Nasal vs Oronasal CPAP for OSA Treatment: A Meta-Analysis. *Chest* 2018;153:665-74.

## APPENDICES






Figure 1: Consort flow diagram



**Figure 2: Effect of mask type on SpO<sub>2</sub> and PtcCO<sub>2</sub> parameters in patients with neuromuscular diseases**

**Legend: ODI, Oxygen desaturation index; tCO<sub>2</sub>, transcutaneous carbon dioxide; SECI, Side effect to CPAP inventory.**



**Figure 3: Effect of usual vs alternative mask on SpO<sub>2</sub> and PtcCO<sub>2</sub> parameters in patients with neuromuscular diseases**

**Legend: ODI, Oxygen desaturation index; tcCO<sub>2</sub>, transcutaneous carbon dioxide; SECI, Side effect to CPAP inventory.**

**Table 1: demographics and ventilator settings**

	Whole cohort (N=30)	Nasal mask (N=17)	Oronasal mask (N=13)	p-value
<b>Sex (M)</b>	16 (53.3)	11 (64.7)	5 (38.5)	0.153
<b>Age (years)</b>	46.7 [41.6 ; 56.9]	46.6 [40.5 ; 56.9]	46.7 [44.4 ; 55.7]	0.535
<b>BMI (Kg/m<sup>2</sup>)</b>	26 [22.3 ; 29.7]	25.7 [19.5 ; 29.2]	26.4 [23.1 ; 31.2]	0.475
<b>Neuromuscular disease</b>				
<i>Duchenne muscular dystrophy</i>	2 (6.7)	2 (11.8)	0 (0)	0.368
<i>Myotonic dystrophy</i>	11 (36.7)	4 (23.5)	7 (53.8)	.
<i>Limb-girdle dystrophy</i>	4 (13.3)	2 (11.8)	2 (15.4)	.
<i>Spinal muscular atrophy</i>	3 (10)	2 (11.8)	1 (7.7)	.
<i>Other neuromuscular diseases</i>	10 (33.3)	7 (41.2)	3 (23.1)	.
<b>Ventilation mode</b>				
<i>Pressure support</i>	26 (86.7)	15 (88.2)	11 (84.6)	0.773
<i>Hybrid*</i>	4 (13.3)	2 (11.8)	2 (15.4)	.
<b>NIV delay (years)</b>	7.5 [4 ; 13]	8 [4 ; 13]	7 [6 ; 10]	0.901
<b>IPAP (cmH20)</b>	15.5 [14 ; 17]	15 [14 ; 17]	16 [14 ; 19]	0.588
<b>*IPAP min (cmH20)</b>	12.5 [12 ; 14.5]	14.5 [13 ; 16]	12 [12 ; 12]	0.308
<b>*IPAP max (cmH20)</b>	21.5 [15.5 ; 24.5]	21.5 [19 ; 24]	18.5 [12 ; 25]	1.00
<b>Vt (L)</b>	425.5 [360 ; 520]	434.5 [337.4 ; 500]	380 [360 ; 635]	0.769
<b>EPAP (cmH20)</b>	6 [4 ; 8]	6 [4 ; 8]	6 [5 ; 8]	0.553
<b>Back up rate (cycle/minutes)#</b>	14 [12 ; 16]	14 [12 ; 15]	15.5 [14 ; 16]	0.055
<b>Mean adherence (hour)#</b>	7.3 [5.1 ; 10.1]	7.2 [5.5 ; 8.6]	8.6 [5.1 ; 10.7]	0.549
<b>Residual AHI (events/h)#</b>	1.7 [0.4 ; 8.2]	2.5 [0.4 ; 11.9]	1 [0.2 ; 2.4]	0.278

BMI, Body mass index; NIV, Noninvasive ventilation; IPAP, Inspiratory positive airway pressure; Vt,

Tidal volume; EPAP, Expiratory positive airway pressure; AHI, Apnea Hypopnea index.

Results are expressed as number (%) or median [IQR].

p-value are given for the differences at baseline between patients using nasal compared to those using oronasal interface.

# reported by built-in NIV softwares



**Table 2: Follow-up variables during the week with both interfaces**

	Nasal Mask week (n=30)	Oronasal Mask week (n=30)	p-value	Usual mask week (n=30)	Alternative mask week (n=30)	p-value
Patients reporting interface problems	8 (26.7)	11 (36.7)	0.41	2 (6.7)	17 (56.7)	<.01
Home care providers intervention	4 (13.3)	2 (6.7)	0.39	0 (0)	6 (20)	<.01
Mean adherence (hour)*	7.1 [4.4 ; 8.8]	6.8 [2.4 ; 9.4]	0.82	7.4 [6.7 ; 9.4]	5.3 [1.3 ; 8.8]	0.02
Residual AHI (event/hour)*	3 [0.5 ; 14.3]	3.7 [0.9 ; 7.2]	0.69	2.7 [0.8 ; 11.8]	4.4 [1.2 ; 14.2]	0.51
Leaks (L/min) : median*†	3.6 [0 ; 7.2]	2.1 [0 ; 6.9]	0.79	3 [0 ; 6]	2.4 [0 ; 10.8]	1.00
Leaks (L/min) : mean*‡	31.7 [27.5 ; 55.1]	34.2 [31.6 ; 39.6]	0.88	33.9 [29.1 ; 36.9]	39.1 [30.2 ; 55.1]	0.45

AHI, Apnea Hypopnea Index

Results are expressed as number (%) or median [IQR].

\* Extracted from NIV built-in software's during each treatment period

† Median non-intentional leaks in patients using Resmed® ventilator

‡ Mean total leaks in patients using Phillips® ventilator

**Table 3: Side effects according to the type of mask (details of the SECI score)**

<b>Modified SECI</b>	<b>Nasal mask</b>	<b>Oronasal mask</b>	<b>p-value</b>	<b>Usual mask</b>	<b>Alternative mask</b>	<b>p-value</b>
<b>TOTAL SCORE (/225)</b>	71 [58 ; 92]	82 [63 ; 92]	0.493	67 [58 ; 87]	84 [62 ; 104]	0.063
<b>SIDE EFFECTS</b>						
<i>Frequency (/75)</i>	26 [22 ; 40]	29 [25 ; 35]	0.437	27 [21 ; 35]	29.5 [25 ; 37]	0.224
<i>Magnitude(/75)</i>	24 [20 ; 35]	30 [22 ; 32]	0.582	23 [20 ; 32]	30 [22 ; 35]	0.161
<i>Perceived impact on adherence (/75)</i>	16.5 [15 ; 25]	17 [15 ; 26]	0.877	15 [15 ; 19]	21.5 [16 ; 27]	<.01
<b>INCOMFORT RELATED TO</b>						
<i>Blocked up nose (/15)</i>	6 [3 ; 7]	4 [3 ; 7]	0.159	5 [3 ; 7]	6 [3 ; 8]	0.515
<i>Runny nose (/15)</i>	5 [3 ; 7]	3 [3 ; 6]	0.105	5 [3 ; 7]	3 [3 ; 6]	0.390
<i>Nose bleed (/15)</i>	3 [3 ; 3]	3 [3 ; 3]	0.661	3 [3 ; 3]	3 [3 ; 3]	0.460
<i>Dry mouth (/15)</i>	5 [3 ; 8]	5 [3 ; 8]	0.403	5 [3 ; 8]	5 [3 ; 8]	0.950
<i>Irritated eyes (/15)</i>	4.5 [3 ; 8]	3 [3 ; 7]	0.670	3 [3 ; 7]	4.5 [3 ; 8]	0.699
<i>Upset bowel (/15)</i>	3 [3 ; 7]	3 [3 ; 7]	0.980	3 [3 ; 7]	3 [3 ; 9]	0.769
<i>Transient deafness (/15)</i>	3 [3 ; 3]	3 [3 ; 3]	0.788	3 [3 ; 3]	3 [3 ; 3]	0.534
<i>Using NIV in front of others (/15)</i>	3 [3 ; 5]	3 [3 ; 7]	0.226	3 [3 ; 4]	3 [3 ; 5]	0.353
<i>Increased number of awakenings (/15)</i>	6 [3 ; 9]	7 [4 ; 10]	0.604	7 [3 ; 8]	7.5 [4 ; 11]	0.255
<i>Mask pressure (/15)</i>	5.5 [3 ; 8]	7 [4 ; 9]	0.140	6 [3 ; 7]	8 [4 ; 10]	0.083
<i>Mask leakage (/15)</i>	6 [4 ; 9]	7 [4 ; 9]	0.676	6 [4 ; 8]	7.5 [4 ; 12]	0.375
<i>Cold air (/15)</i>	3 [3 ; 6]	3 [3 ; 6]	0.958	3 [3 ; 4]	3 [3 ; 6]	0.549
<i>Noise (/15)</i>	3 [3 ; 8]	4 [3 ; 8]	0.559	3 [3 ; 7]	3.5 [3 ; 8]	0.495
<i>Problems exhaling (/15)</i>	3.5 [3 ; 7]	3 [3 ; 5]	0.278	3 [3 ; 5]	3.5 [3 ; 7]	0.231
<i>Anxiety during treatment (/15)</i>	3 [3 ; 7]	5 [3 ; 8]	0.095	3 [3 ; 7]	4 [3 ; 9]	0.157



### ORONASAL MASK

- are used by 25% of patients with neuromuscular diseases (NMD) treated with nocturnal NIV
- may increase upper-airway resistances by pushing the mandible backward

### HYPOTHESIS



### NASAL MASK

- Would improve efficacy and reduce side effects compared to oronasal masks in patients with NMD

N=30

cross-over randomized trial  
 1-week period with nasal mask  
 1-week period oronasal mask

### ORONASAL MASK



VS

### NASAL MASK



- Nasal masks did not improve NIV efficacy or reduce side effects compared to oronasal masks in NMD treated with NIV

### USUAL MASK

VS

### ALTERNATIVE MASK

- The efficacy of NIV was reduced during the transition from a type of interface to another, requiring a close monitoring

Mean nocturnal SpO2 (p=0.04); O2 desat index (p=0.01);  
 Mean tcCO2 (p=0.048); Side-effects (p=0.08)